Skip to main content

Morphosys, GeneFrontier Expand HuCAL Deal to Include Antibody Development

NEW YORK (GenomeWeb News) — Morphosys today said it has expanded a 2-year-old marketing agreement with GeneFrontier to include HuCAL-based research, and the sales of any resulting antibody products.
 
The original agreement, signed in 2004, gave Tokyo-based GeneFrontier rights to market the Human Combinatorial Antibody Library technology in Japan for research and therapeutic applications.
 
Under the expanded deal, GeneFrontier will use the HuCAL Gold library to develop antibodies, and it has installed the technology in its Tokyo lab to conduct the research.
 
GeneFrontier paid Morphosys “a financial compensation” for access to the technology, Morphosys said. The companies also will share commercialization rights to antibodies discovered by GeneFrontier and its research partners.
 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.